This study evaluates the pharmacokinetic drug-drug interactions of repeated co-administration of HUC2A-752-A and HUC2A-752-B compared to monotherapy of each agent in healthy adults
Healthy adult volunteers
Individuals with a body weight between 50.0 kg and 90.0 kg and a BMI between 18.5 kg/m² and 29.9 kg/m²
Individuals with a history or presence of clinically significant diseases of the following systems: hepatobiliary, renal, neurological, immunological, respiratory, gastrointestinal, endocrine, hematologic/oncologic, cardiovascular , musculoskeletal, urological, psychiatric, or sexual dysfunction.
Individuals with a history of gastrointestinal diseases or gastrointestinal surgeries that could affect the safety or pharmacokinetic evaluation of the investigational product.
Individuals with a history of hypersensitivity or clinically significant hypersensitivity reactions to losartan, pitavastatin, ezetimibe, angiotensin receptor blockers, statins, or any other medications.
Sequential
Losartan (COZZAR®)
DrugHUC2A-752-A
Pitavastatin plus Ezetemibe
DrugHUC2A-752-B
AUCtau,ss
Area Under the Curve
Cmax,ss
Maximum concentration at steady state
Tmax,ss
Time to maximum concentration at steady state
t1/2
Half-life
CLss/F
Apparent Clearance
Vdss/F
Apparent Volume of Distribution at Steady State
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: